vs
Side-by-side financial comparison of FLOWERS FOODS INC (FLO) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.2× FLOWERS FOODS INC). On growth, FLOWERS FOODS INC posted the faster year-over-year revenue change (11.0% vs -3.5%). Over the past eight quarters, Organon & Co.'s revenue compounded faster (-4.7% CAGR vs -11.6%).
Flowers Foods, headquartered in Thomasville, Georgia, is a producer and marketer of packaged bakery foods in the United States. The company operates 44 bakeries across 19 states that produce a variety of products, including bread, buns, rolls, snack cakes, pastries, and tortillas. As of February 2013, Flowers Foods had grown to be the "second-largest baking company in the United States."
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
FLO vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.5B |
| Net Profit | — | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | — | — |
| Net Margin | — | 10.0% |
| Revenue YoY | 11.0% | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | — | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.2B | $1.6B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $1.2B | $1.6B | ||
| Q2 24 | $1.6B | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | $39.5M | $-205.0M | ||
| Q3 25 | $58.4M | $160.0M | ||
| Q2 25 | $53.0M | $145.0M | ||
| Q1 25 | — | $87.0M | ||
| Q4 24 | $65.0M | $109.0M | ||
| Q3 24 | $67.0M | $359.0M | ||
| Q2 24 | $73.0M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | -9.8% | ||
| Q3 25 | 7.5% | 15.2% | ||
| Q2 25 | 5.5% | 14.4% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | 7.6% | 8.1% | ||
| Q3 24 | 7.8% | 13.1% | ||
| Q2 24 | 6.4% | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | 3.2% | -13.6% | ||
| Q3 25 | 4.7% | 10.0% | ||
| Q2 25 | 3.4% | 9.1% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | 5.5% | 6.8% | ||
| Q3 24 | 5.5% | 22.7% | ||
| Q2 24 | 4.6% | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $0.19 | $-0.78 | ||
| Q3 25 | $0.28 | $0.61 | ||
| Q2 25 | $0.25 | $0.56 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | $0.31 | $0.42 | ||
| Q3 24 | $0.32 | $1.38 | ||
| Q2 24 | $0.34 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $4.2B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $16.7M | $574.0M | ||
| Q3 25 | $11.0M | $672.0M | ||
| Q2 25 | $7.3M | $599.0M | ||
| Q1 25 | — | $547.0M | ||
| Q4 24 | $15.0M | $675.0M | ||
| Q3 24 | $6.9M | $763.0M | ||
| Q2 24 | $15.8M | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $8.6B | ||
| Q3 25 | $1.7B | $8.8B | ||
| Q2 25 | $1.8B | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | $1.1B | $8.9B | ||
| Q3 24 | $1.1B | $8.7B | ||
| Q2 24 | $1.0B | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $752.0M | ||
| Q3 25 | $1.4B | $906.0M | ||
| Q2 25 | $1.4B | $733.0M | ||
| Q1 25 | — | $542.0M | ||
| Q4 24 | $1.4B | $472.0M | ||
| Q3 24 | $1.4B | $493.0M | ||
| Q2 24 | $1.4B | $144.0M |
| Q1 26 | — | — | ||
| Q4 25 | $4.3B | $12.9B | ||
| Q3 25 | $4.3B | $13.6B | ||
| Q2 25 | $4.3B | $13.5B | ||
| Q1 25 | — | $13.2B | ||
| Q4 24 | $3.4B | $13.1B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.4B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | 11.49× | ||
| Q3 25 | 1.23× | 9.74× | ||
| Q2 25 | 1.26× | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | 0.75× | 18.81× | ||
| Q3 24 | 0.77× | 17.75× | ||
| Q2 24 | 0.76× | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $125.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $54.4M | $141.0M | ||
| Q3 25 | $130.8M | $264.0M | ||
| Q2 25 | $135.6M | $220.0M | ||
| Q1 25 | — | $75.0M | ||
| Q4 24 | $113.9M | $390.0M | ||
| Q3 24 | $63.3M | $141.0M | ||
| Q2 24 | $105.1M | $332.0M |
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $96.0M | ||
| Q3 25 | $100.0M | $218.0M | ||
| Q2 25 | $110.1M | $181.0M | ||
| Q1 25 | — | $43.0M | ||
| Q4 24 | $88.6M | $335.0M | ||
| Q3 24 | $35.4M | $99.0M | ||
| Q2 24 | $71.8M | $300.0M |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 6.4% | ||
| Q3 25 | 8.0% | 13.6% | ||
| Q2 25 | 7.1% | 11.4% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | 7.4% | 21.0% | ||
| Q3 24 | 2.9% | 6.3% | ||
| Q2 24 | 4.6% | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 3.0% | ||
| Q3 25 | 2.5% | 2.9% | ||
| Q2 25 | 1.6% | 2.4% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | 2.1% | 3.5% | ||
| Q3 24 | 2.3% | 2.7% | ||
| Q2 24 | 2.1% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.38× | — | ||
| Q3 25 | 2.24× | 1.65× | ||
| Q2 25 | 2.56× | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | 1.75× | 3.58× | ||
| Q3 24 | 0.94× | 0.39× | ||
| Q2 24 | 1.44× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLO
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
